Application of thin layer chromatography in the analysis of efavirenz
Aim. To carry out the integrated study of visualization conditions of efavirenz on TLC-plates with aplication of standard and particular colored reagents, and the chromatographic behavior of efavirenz using standard mobile phases.
Results and discussion. It has been shown that such widely used color reagents as UV-light, Erdmann reagent, Froehde reagent, Liebermann reagent, sulfuric acid, Marquis reagent, Mandelin reagent, acidified iodoplatinate solution, iodine vapor can be used for efavirenz detection on chromatographic plates. Efavirenz gives the positive detection results with reagents used in the TLC-screening of extracts from the biological material for substances of basic, acid and neutral nature. The chromatographic mobility of efavirenz has been studied in 17 solvents systems; the systems are used as standard mobile phases according to the recommendations of the International Association of Forensic Toxicologists for TLC-screening of organic compounds of acid, neutral and basic nature, and as well as in the general TLC-screening of organic substances in the Ukrainian forensic toxicological laboratories.
Experimental part. The chromatographic plates Sorbfil® PTLC-IIH-UV and Merck® TLC Silica gel 60G were used as thin layers.
Conclusions. The behavior of efavirenz when developing on TLC-plates with two types of a substrate (plastic and glass) and with/without a luminophor with commonly used colored reagents has been studied. The Rf values of efavirenz under chromatographing conditions in the standard solvent systems used for TLC-screening of organic compounds of acid, neutral and basic nature have been set.
Usach, I.; Melis, V.; Peris, J.-E. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. Journal of the International AIDS Society 2013, 16 (1), 18567. https://doi.org/10.7448/ias.16.1.18567.
Waters, L.; John, L.; Nelson, M. Non-nucleoside reverse transcriptase inhibitors: a review. International Journal of Clinical Practice 2007, 61 (1), 105–118. https://doi.org/10.1111/j.1742-1241.2006.01146.x.
De Clercq, E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Research 1998, 38 (3), 153–179. https://doi.org/10.1016/S0166-3542(98)00025-4.
Rakhmanina, N. Y.; van den Anker, J. N. Efavirenz in the therapy of HIV infection. Expert Opinion on Drug Metabolism & Toxicology 2010, 6 (1), 95–103. https://doi.org/10.1517/17425250903483207.
Bastos, M. M.; Costa, C. C. P.; Bezerra, T. C.; da Silva, F. d. C.; Boechat, N. Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry. Eur. J. Med. Chem. 2016, 108, 455–465. https://doi.org/10.1016/j.ejmech.2015.11.025.
Best, B. M.; Goicoechea, M. Efavirenz – Still First-line King? Expert Opinion on Drug Metabolism & Toxicology 2008, 4 (7), 965–972. https://doi.org/10.1517/17425255.4.7.965.
Andany, N.; Gold, W. L. Single-tablet antiretroviral treatment (once daily). Canadian Medical Association Journal 2016, 188 (13), 971. https://doi.org/10.1503/cmaj.151412.
Kenedi, C. A.; Goforth, H. W. A Systematic Review of the Psychiatric Side-Effects of Efavirenz. AIDS and Behavior 2011, 15 (8), 1803–1818. https://doi.org/10.1007/s10461-011-9939-5.
Decloedt, E. H.; Maartens, G. Neuronal toxicity of efavirenz: a systematic review. Expert Opinion on Drug Safety 2013, 12 (6), 841–846. https://doi.org/10.1517/14740338.2013.823396.
Abers, M. S.; Shandera, W. X.; Kass, J. S. Neurological and Psychiatric Adverse Effects of Antiretroviral Drugs. CNS Drugs 2014, 28 (2), 131–145. https://doi.org/10.1007/s40263-013-0132-4.
Mutwa, P. R.; Fillekes, Q.; Malgaz, M.; Tuyishimire, D.; Kraats, R. v. d.; Boer, K. R.; Burger, D. M.; van Schaik, R. H. N.; Muganga, N.; Geelen, S. P. M. Mid-Dosing Interval Efavirenz Plasma Concentrations in HIV-1–Infected Children in Rwanda: Treatment Efficacy, Tolerability, Adherence, and the Influence of CYP2B6 Polymorphisms. JAIDS Journal of Acquired Immune Deficiency Syndromes 2012, 60 (4), 400–404. https://doi.org/10.1097/QAI.0b013e3182569f57.
Fillekes, Q.; Natukunda, E.; Balungi, J.; Kendall, L.; Bwakura-Dangarembizi, M.; Keishanyu, R.; Ferrier, A.; Lutakome, J.; Gibb, D. M.; Burger, D. M.; Walker, A. S. Pediatric Underdosing of Efavirenz: A Pharmacokinetic Study in Uganda. JAIDS Journal of Acquired Immune Deficiency Syndromes 2011, 58 (4), 392–398. https://doi.org/10.1097/QAI.0b013e318235e560.
Mollan, K. R.; Smurzynski, M.; Eron, J. J.; Daar, E. S.; Campbell, T. B.; Sax, P. E.; Gulick, R. M.; Na, L.; O’Keefe, L.; Robertson, K. R.; Tierney, C. Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide: An Analysis of Trial Data. Annals of Internal Medicine 2014, 161 (1), 1–10. https://doi.org/10.7326/m14-0293.
Moffat A.C.; Osselton M.D.; Widdop B. Clarke’s analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material. 4 ed.; Pharmaceutical Press: London, 2011.
Jickells, S.; Negrusz, A., Clarke’s Analytical Forensic Toxicology. Pharmaceutical Press: London, 2008.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Abbreviated key title: J. Org. Pharm. Chem.
ISSN 2518-1548 (Online), ISSN 2308-8303 (Print)